|By PR Newswire||
|September 5, 2014 07:30 AM EDT||
NEW YORK, Sept. 5, 2014 /PRNewswire/ -- Stellar Biotechnologies, Inc. (OTCQB: SBOTF) is an emerging contender in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, and infectious diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology.
The Company's KLH protein is so unique because it can be sourced from the blood of only one rare sea animal, the California Keyhole Limpet which SBOTF farms in its own facility. The Keyhole Limpet can only be found off the coast of central California to Northern Baja. Stellar's headquarters and aquaculture facility are situated in the center of those two locations. This is certainly an advantage that creates entry barriers but also creates big systemic vulnerability issues as well. How long it takes at maturity to produce the material and the ultimate quality level are still to be learned. This can be a decided advantage for aggressive traders and speculators but must be carefully considered as a risk for longer term investors.
An analyst report which details the current situation, an overview of the company and analyst comments can be viewed in its entirety by using the link below. There is no cost obligation required to view this report:
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. Research report provided for informational purposes. This document, article or report is written and authored by Michael Anderegg, Chartered Financial Analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
A full disclaimer can be found by viewing the full analyst report.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.
Feb. 11, 2016 12:20 PM EST
Feb. 11, 2016 12:00 PM EST Reads: 201
Feb. 11, 2016 12:00 PM EST
Feb. 11, 2016 11:30 AM EST
Feb. 11, 2016 11:30 AM EST Reads: 243
Feb. 11, 2016 11:15 AM EST Reads: 277
Feb. 11, 2016 11:07 AM EST
Feb. 11, 2016 11:00 AM EST Reads: 413
Feb. 11, 2016 11:00 AM EST Reads: 118
Feb. 11, 2016 11:00 AM EST Reads: 241
Feb. 11, 2016 10:33 AM EST
Feb. 11, 2016 10:30 AM EST
Feb. 11, 2016 10:15 AM EST
Feb. 11, 2016 10:00 AM EST Reads: 394
Feb. 11, 2016 09:58 AM EST